Global health R&D benefits rich countries too, study argues

23 Sep 2025 | News
Drug development
R&D Funding

Ninety per cent of funding goes to wealthy states, and innovations spill over into rich-world treatments, says think tank 

By David Matthews

A 14-year old girl in Addis Ababa getting the HPV vaccine during the HPV vaccine in January 2021. Photo credits: WHO

As the US cuts back on its funding for global health research, a new study has argued that this money largely stays within rich countries, and leads to inventions that are later repurposed for people in wealthy, donor states. 

Under Donald Trump’s second administration, the US has closed the US Agency for International Development, as well as seeking to halt overseas sub-awards from the country’s National Institutes for Health (NIH). 

While it has backtracked and reinstated some NIH awards, Washington’s turn away from global health…

Discover the latest in research funding every Tuesday with Funding Newswire. Dive into detailed articles with our monthly or yearly subscriptions or start with a free trial

NOTE: if you're a part of one of our Network member organisations, you get free access by signing up with your institutional email. Verify your eligibility here.

The email address is not made public. It will only be used if you need to be contacted about your account or for opted-in notifications.

Several special characters are allowed, including space, period (.), hyphen (-), apostrophe ('), underscore (_), and the @ sign.

Provide a password for the new account in both fields.

My Profile

Related News